siRNAN6-YTHDF1,EZH2-IL-6NASH-HCC

Lina Wang1, Lefan Zhu2, Cong Liang3

  • 1Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Journal of hepatology
|July 17, 2023
PubMed
概括

通过通过EZH2-IL-6信号传递抑制CD8+T细胞,YTHDF1促进与非酒精性脂肪肝相关的肝细胞癌 (NASH-HCC). 向YTHDF1可以提高NASH-HCC中抗PD-1疗法的疗效.